Catecholamine mechanisms in the prefrontal cortex: proven strategies for enhancing higher cognitive function

Robbins, 1996, Dissociating executive functions of the prefrontal cortex, Philos Trans R Soc Lond B Biol Sci, 351, 1463, 10.1098/rstb.1996.0131 Price, 1996, Networks related to the orbital and medial prefrontal cortex; a substrate for emotional behavior?, Prog Brain Res, 107, 523, 10.1016/S0079-6123(08)61885-3 Arnsten, 2002, Neurobiology of attention regulation and its disorders, 99 Rubia, 2003, Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection, Neuroimage, 20, 351, 10.1016/S1053-8119(03)00275-1 Aron, 2011, From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses, Biol Psychiatry, 69, e55, 10.1016/j.biopsych.2010.07.024 Chambers, 2006, Executive “brake failure” following deactivation of human frontal lobe, J Cog Neurosci, 18, 444 Perlstein, 2001, Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia, Am J Psychiatry, 158, 1105, 10.1176/appi.ajp.158.7.1105 Drevets, 1997, Subgenual prefrontal cortex abnormalities in mood disorders, Nature, 386, 824, 10.1038/386824a0 Arnsten, 2012, Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders, J Am Acad Child Adolesc Psychiatry, 51, 356, 10.1016/j.jaac.2012.01.008 Shaw, 2009, Development of cortical asymmetry in typically developing children and its disruption in attention-deficit/hyperactivity disorder, Arch Gen Psychiatry, 66, 888, 10.1001/archgenpsychiatry.2009.103 Makris, 2007, Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder, Cereb Cortex, 17, 1364, 10.1093/cercor/bhl047 Casey, 2007, Frontostriatal connectivity and its role in cognitive control in parent-child dyads with adhd, Am J Psychiatry, 164, 1729, 10.1176/appi.ajp.2007.06101754 Robbins, 2009, The neuropsychopharmacology of fronto-executive function: monoaminergic modulation, Annu Rev Neurosci, 32, 267, 10.1146/annurev.neuro.051508.135535 Goldman-Rakic, 1995, Cellular basis of working memory, Neuron, 14, 477, 10.1016/0896-6273(95)90304-6 Wang, 2007, Alpha2a-adrenoceptors strengthen working memory networks by inhibiting camp-hcn channel signaling in prefrontal cortex, Cell, 129, 397, 10.1016/j.cell.2007.03.015 Arnsten, 2012, Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses, Neuron, 76, 223, 10.1016/j.neuron.2012.08.038 Arnsten, 2010, Dynamic network connectivity: a new form of neuroplasticity, Trends Cog Sci, 14, 365, 10.1016/j.tics.2010.05.003 Li, 1994, Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys, Behav Neural Biol, 62, 134, 10.1016/S0163-1047(05)80034-2 Ma, 2005, Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys, Biol Psychiatry, 57, 192, 10.1016/j.biopsych.2004.11.004 Ma, 2003, Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys, Neuroreport, 14, 1013 Vijayraghavan, 2007, Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory, Nat Neurosci, 10, 376, 10.1038/nn1846 Li, 2010, Dopamine D(1) receptor-mediated enhancement of nmda receptor trafficking requires rapid pkc-dependent synaptic insertion in the prefrontal neurons, J Neurochem, 114, 62 Arnsten, 2009, Stress signalling pathways that impair prefrontal cortex structure and function, Nat Rev Neurosci, 10, 410, 10.1038/nrn2648 Devilbiss, 2008, Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness, Biol Psychiatry, 64, 626, 10.1016/j.biopsych.2008.04.037 Lundqvist, 2009 Berridge, 2012, Attention deficit hyperactivity disorder Arnsten, 1996, The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder, Arch Gen Psychiatry, 53, 448, 10.1001/archpsyc.1996.01830050084013 Cedarbaum, 1977, Catecholamine receptors on locus coeruleus neurons: pharmacological characterization, EurJ Pharmacol, 44, 375, 10.1016/0014-2999(77)90312-0 Uhlen, 1995, Comparison of the binding activities of some drugs on alpha 2a, alpha 2b and alpha 2c-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig, Pharmacol Toxicol, 76, 353, 10.1111/j.1600-0773.1995.tb00161.x Berridge, 2012, Noradrenergic modulation of wakefulness/arousal, Sleep Med Rev, 16, 187, 10.1016/j.smrv.2011.12.003 Kauser, 2013, Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline, Neuroscience, 254, 110, 10.1016/j.neuroscience.2013.09.023 Gyoneva, 2013, Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors, J Biol Chem, 288, 15291, 10.1074/jbc.M113.458901 Arnsten, 2012, Guanfacine for the treatment of cognitive disorders: a century of discoveries at yale, Yale J Biol Med, 85, 45 Shenker, 1992, The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology, Adv Pediatr, 39, 337 Wender, 1985, Pharmacological treatment of attention deficit disorder, residual type in adults, Psychopharmacol Bull, 21, 222 Greenhill, 2001, Clinical effects of stimulant medication in adhd, 31 Wilens, 2004, Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study, J Clin Psychopharmacol, 24, 36, 10.1097/01.jcp.0000106223.36344.df erridge, 2011, Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder, Biol Psychiatry, 69, e101, 10.1016/j.biopsych.2010.06.023 del Campo, 2013, A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for adhd and its treatment, Brain, 136, 3252, 10.1093/brain/awt263 Kuczenski, 1995, Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine, J Neurosci, 15, 1308, 10.1523/JNEUROSCI.15-02-01308.1995 Berridge, 2006, Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function, Biol Psychiatry, 60, 1111, 10.1016/j.biopsych.2006.04.022 Kuczenski, 2002, Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine, J Neurosci, 22, 7264, 10.1523/JNEUROSCI.22-16-07264.2002 Drouin, 2006, Methylphenidate enhances noradrenergic transmission and suppresses mid- and long-latency sensory responses in the primary somatosensory cortex of awake rats, J Neurophysiol, 96, 622, 10.1152/jn.01310.2005 Biederman, 2003, Pharmacotherapy for attention-deficit/hyperactivity disorder (adhd) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without adhd, J Clin Psychiatry, 64, 3 Wilens, 2003, Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature, Pediatrics, 111, 179, 10.1542/peds.111.1.179 Schmeichel, 2013, Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants, Neuropsychopharmacology, 38, 1078, 10.1038/npp.2013.6 Giros, 1994, Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters, J Biol Chem, 269, 15985, 10.1016/S0021-9258(17)33961-3 Gu, 1994, Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence, J Biol Chem, 269, 7124, 10.1016/S0021-9258(17)37256-3 Moron, 2002, Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines, J Neurosci, 22, 389, 10.1523/JNEUROSCI.22-02-00389.2002 Bymaster, 2002, Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder, Neuropsychopharmacology, 27, 699, 10.1016/S0893-133X(02)00346-9 Carboni, 1990, Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals, J Neurochem, 55, 1067, 10.1111/j.1471-4159.1990.tb04599.x Schmeichel, 2012, A selective dopamine reuptake inhibitor imporves prefrontal cortex-dependent cognitive function: potential relevant to attention deficit hyperactivity disorder, Neuropharmacology, 64, 321, 10.1016/j.neuropharm.2012.07.005 Gamo, 2010, Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine d1 receptors, J Am Acad Child Adolesc Psychiatry, 49, 1011, 10.1016/j.jaac.2010.06.015 Spencer, 2012, Psychostimulants act within the prefrontal cortex to improve cognitive function, Biol Psychiatry, 72, 221, 10.1016/j.biopsych.2011.12.002 Spencer, 2014, The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex, Biol Psychiatry Arnsten, 2005, Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine d1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder, Behav Brain Funct, 1, 2, 10.1186/1744-9081-1-2 Schmeichel, 2013, A Selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder, Neuropharmacology, 64, 321, 10.1016/j.neuropharm.2012.07.005